AT1 FY21 - General Discussion + FA, page-215

Hiya, sorry for the delay, couldn't get back to this topic till late. Too many US company earnings releases to catch up on before Fri market close

Adding to above info I posted:
- NanoDx is private diagnostics company, Boston, USA
- correction, NanoDx raised US$18m in private investor funding (July'20)
- no regulatory approvals yet; though company is aiming for EU CE + US FDA approvals

- new clinical trial (started 22 Oct'20) registered for two NanoDx kits (blood + saliva).
https://clinicaltrials.gov/ct2/show/NCT04597216?term=nanodx&draw=2&rank=1

- there is no public info on their test's usage requirements, diagnosis IFUs or result ranges...so no idea how well it works. There is basic info about their proprietary tech on their website + videos etc on how it works.

- one interesting tidbit, NanaDx tech must be innovative, as it has an ongoing project, funded by EU Commission Diagnostics improvement drive to get more accurate Covid19 POCTs.
EU all project list: https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/diagnostics_en
NanoDx EU project detail: https://eithealth.eu/project/nanodx-covid-19/

NanoDx EU Project goals: a more sensitive means of diagnosing COVID-19 with a paper-based test that combines innovations in two technologies: use of nanoporous silicon and an immuno protemic, or protein-based, test. The nanoporous silicon improves the ability of the test to capture tell-tale biomarkers that indicate infection, while keeping those biomarkers stable. The technology involved in the test will allow for diagnosing even low concentrations of viral infection, as well as giving prognostic information that can help in patient management.

As I mentioned earlier, assuming this test makes it to market some day, the main competition will be in US + EU regions...which don't affect AT1's Ag target markets announced.
=================================
PS: funnily, going down the EU improvement project rabbit hole, I came across several US/EU companies already commercialised (OR close to release) 2nd gen Ag RDTs (nasal, saliva) that are reaching 96% to 98%+ sensitivity. These Ag RDTs are improving at an astonishing rate to 100% accuracy...previously would have taken several years to move POCT needle from 56% to 98%+ accuracy for anything...but I guess shouldn't be surprised with the intense govt + private funding pouring into this field.

These 2nd gen Ag tests hitting the market may cause issues for AT1's target market like India/AU...unless AccBio also releases improved versions fairly soon OR AT1 partners with someone else's improved version (eg: over next 2 qtrs). Its all bonus stuff so not huge core biz concern..